Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Abbott issues US device correction for some glucose monitors over faulty readings risk - 2Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- 3These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- 4Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- 5‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- Fireballs and a full moon. Here’s how to see two celestial events this week
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Figure out how to Amplify Your Open Record Reward
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
- Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- Support Your Investment funds with These Individual accounting Thoughts
- The German series proving subtitles can be sexy — and wildly addictive
- Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
- People with depression can treat themselves at home with new device
